Clinical trials: Diabetic Macular Edema, open to volunteers
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution, High-speed Multimodal Ophthalmic Imaging
Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IMA-MODE (NCT04129021)
- Testing
- High-resolution retinal imaging through adaptive optics, High-resolution retinal imaging through holographic systems
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP).
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetic Retinopathy Visually Threatening, Diabetic Macular Edema
- Trial name
- SMART-PRP (NCT06549023)
- Testing
- Single-session panretinal PRP (SS-PRP), Multiple-session panretinal PRP (MS-PRP)
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Diabetic Macular Edema
OCT-Based Screening for Early Retinal Changes in Asymptomatic Diabetic Patients
The goal of this observational study is to detect early retinal changes in people with diabetes who do not have visual symptoms.
- Trial name
- DREAM-OCT (NCT07232225)
- Testing
- Spectral Domain OCT Imaging
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Macular Edema, DME
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
- Trial name
- NCT07199777
- Testing
- SNP318
- Volunteers
- 60 people
- Sponsor
- SciNeuro
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Non-Center, Diabetic Macular Edema
Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification
This study aims to evaluate the progression of non-center-involving diabetic macular edema in the early postoperative period following phacoemulsification.
- Conditions
- Non-Center, Diabetic Macular Edema, Phacoemulsification
- Trial name
- NCT07038967
- Testing
- Coloured photography, Fluorescein angiography, Optical coherence tomography
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Diabetic Macular Edema, Center-involved Diabetic Macular Edema
Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema
The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement…
- Trial name
- DAPA-DME (NCT06845163)
- Testing
- Dapagliflozin, Anti-VEGF drug
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Alexandria University
Age Related Macular Degeneration, Diabetic Retinopathy
Effect of Video Viewing on Intravitreal Injection Experience
Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing…
- Conditions
- Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization, Retinal Vein Occlusion
- Trial name
- NCT07002372
- Testing
- Procedure video viewing
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetic Macular Edema
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
Diabetic macular oedema (DME) is the main cause of visual impairment (or visual acuity) in patients with diabetic retinopathy, as it leads to progressive thickening of the retina, which in the long term leads to progressive death…
- Trial name
- EMMA (NCT04910503)
- Testing
- Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Diabetic Macular Edema
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
- Trial name
- ELAAVATE (NCT06942520)
- Testing
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sierra Eye Associates
Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse.
- Conditions
- Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Diabetic Macular Edema (DME)
- Trial name
- IMLADRIS (NCT06914778)
- Testing
- Blood draw for the laboratory assessment, Urine sample
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hywel Dda Health Board
Macular Edema, Macular Degeneration
Implementation of the Intravitreal Injection Administered by Nurses
Introduction: Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision.
- Conditions
- Macular Edema, Macular Degeneration, Diabetic Macular Edema
- Trial name
- NCT06511700
- Testing
- It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporacion Parc Tauli
Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME)
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06832657
- Testing
- JMKX003948 Ophthalmic Suspension
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jemincare
Age Related Macular Degeneration, Intravitreal Injections
Aflibercept in Recurrent or Persistent CNV
Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina.
- Conditions
- Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema
- Trial name
- OPHTH-010915 (NCT02669953)
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Medical University of Vienna
Diabetic Macular Edema
Gene Therapy for DME
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME).
- Trial name
- NCT06492876
- Testing
- FT-003
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Frontera Therapeutics
Diabetic Retinopathy, Diabetic Macular Edema
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Anti-vascular Endothelial Growth Factor
- Trial name
- DR (NCT06272565)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Macular Edema
Gene Therapy for Diabetic Macular Edema
FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic…
- Trial name
- NCT05916391
- Testing
- FT-003
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics